To scan or not to scan
DaT is the question
Citation Manager Formats
Make Comment
See Comments

This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
The Food and Drug Administration (FDA) recently approved [123I]ioflupane ([123I]-fluoropropyl βCIT), a dopamine transporter (DAT) radioligand, for SPECT to “assist in the evaluation of adult patients with suspected parkinsonian syndromes (PS).”1 This permits physicians to prescribe [123I]ioflupane SPECT scans as part of clinical practice. Advertisements encourage clinicians to order this and patients to request such scans. The key questions for neurologists are as follows: Do [123I]ioflupane SPECT scans provide useful data beyond clinical evaluation? Does this information improve patient care?
SPECT measurement of the striatal uptake of [123I]ioflupane reflects the integrity of terminal fields of nigrostriatal neurons. People with Parkinson disease (PD) have reduced striatal uptake.2,3 In fact, such scans may be more sensitive than the clinical examination to detect nigrostriatal defects.4 However, loss of striatal DAT occurs in most degenerative PS, including multisystem atrophy (MSA), progressive supranuclear palsy (PSP), and corticobasal disease (CBD).5 Thus, in individual cases, reduced striatal uptake of [123I]ioflupane does not distinguish these different conditions. Most clinical studies focused on whether these scans reliably discriminate PS from disorders that clinically resemble PS but without striatal DAT deficiency.
Multiple studies report that DAT SPECT can distinguish PS from essential tremor (ET). ET is chosen as the comparator disorder for many studies since it has normal striatal DAT. The first published study compared DAT SPECT with initial and 6-month follow-up examinations by a movement disorders expert.6 The goal was to determine whether SPECT predicts the follow-up clinical diagnosis. The subjects had either PS …
AAN Members
We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.
AAN Non-Member Subscribers
Purchase access
For assistance, please contact:
AAN Members (800) 879-1960 or (612) 928-6000 (International)
Non-AAN Member subscribers (800) 638-3030 or (301) 223-2300 option 3, select 1 (international)
Sign Up
Information on how to subscribe to Neurology and Neurology: Clinical Practice can be found here
Purchase
Individual access to articles is available through the Add to Cart option on the article page. Access for 1 day (from the computer you are currently using) is US$ 39.00. Pay-per-view content is for the use of the payee only, and content may not be further distributed by print or electronic means. The payee may view, download, and/or print the article for his/her personal, scholarly, research, and educational use. Distributing copies (electronic or otherwise) of the article is not allowed.
Disputes & Debates: Rapid online correspondence
NOTE: All authors' disclosures must be entered and current in our database before comments can be posted. Enter and update disclosures at http://submit.neurology.org. Exception: replies to comments concerning an article you originally authored do not require updated disclosures.
- Stay timely. Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- 200 words maximum.
- 5 references maximum. Reference 1 must be the article on which you are commenting.
- 5 authors maximum. Exception: replies can include all original authors of the article.
- Submitted comments are subject to editing and editor review prior to posting.